Hepatitis C virus News

A decentralised care and the provision of free direct-acting antiviral agents (DAAs) can produce high rates of cure among people with hepatitis C virus (HCV) infection, according to a large-scale study conducted in India.

A recent research cited in an academic journal titled Nature Medicine suggests that the virus that causes hepatitis C protects itself by blocking signals that call up immune defenses in liver cells.

 Individuals infected with Hepatitis C virus (HCV) may be prone to certain head and neck cancers, a new study has found, pressing the need for screening and treatment for the most common blood-borne virus infection.

The team from the Indian Institute of Science (IISc), Bengaluru, has developed a vaccine for HCV genotype 3a.

 Novel antiviral therapies for hepatitis C virus (HCV) could reduce the prevalence of the blood-borne infection by more than 80 per cent, a new study has found.

Importantly, for the first time, researchers can use urine specimens for one-step screening and diagnosing of HCV infection.

 Researchers have identified "broadly neutralizing" antibodies that protect against infection by multiple, distantly related alphaviruses, including Chikungunya virus, that cause fever and debilitating joint pain.

Of the 22 infected, the youngest is 24 years old, and the remaining are between 50 and 60 years old.

Researchers have developed a new DNA test that can be used to rapidly diagnose Ebola and other pathogens such as Chikungunya and hepatitis C virus.